RG
ODT

Redmile Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Redmile Group’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,162
Closed -$338K – 94
2020
Q3 		$338K Sell
25,162
-607,876
-96% -$17.2M 0.01% 80
2020
Q2 		$26.8M Sell
633,038
-75,000
-11% -$2.43M 0.49% 53
2020
Q1 		$19.5M Sell
708,038
-82,033
-10% -$2.39M 0.55% 44
2019
Q4 		$25.6M Buy
790,071
+16,500
+2% +$511K 0.61% 44
2019
Q3 		$20.1M Buy
773,571
+32,900
+4% +$1.1M 0.67% 45
2019
Q2 		$27.2M Buy
740,671
+263,207
+55% +$6.31M 0.77% 40
2019
Q1 		$10.6M Buy
477,464
+20,513
+4% +$359K 0.31% 54
2018
Q4 		$6.43M Sell
456,951
-148,349
-25% -$2.31M 0.26% 58
2018
Q3 		$11.7M Sell
605,300
-5,300
-0.9% -$108K 0.36% 57
2018
Q2 		$13.5M Buy
610,600
+16,400
+3% +$382K 0.46% 49
2018
Q1 		$12.6M Sell
594,200
-2,700
-0.5% -$63.7K 0.49% 47
2017
Q4 		$14.9M Buy
+596,900
New +$14.1M 0.65% 46

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Redmile Group's ODT Position: Q4 2020 in Review

Redmile Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2020, closing a stake of 25,162 shares — an estimated $338K sold.

Redmile Group first reported a position in ODT in Q4 2017 and held it in 12 quarters. The position peaked at $27.2M in Q2 2019. 94 funds tracked by Wall St. Rank hold ODT as of Q4 2020.

  • Redmile Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Redmile Group sold 25,162 Odonate Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $338K.
  • Redmile Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 12 quarters.
  • Redmile Group's Odonate Therapeutics, Inc. Common Stock position peaked at $27.2M in Q2 2019.
  • 94 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Redmile Group's 13F filing for Q4 2020, filed 16 Feb 2021.